Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...

Dish,” to test anti-amyloid therapies. The approach has already been used to screen thousands of compounds and enables more ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and s ...

Objective: To evaluate in vitro the effect of gamma-secretase inhibition on the survival of dental pulp stem cells. Material and Methods: Sound teeth have been used. Dental pulp stem cells were ...

Down syndrome (DS) is a disorder caused by an extra copy of chromosome 21 that increases expression of genes located on chromosome 21. This leads to a cascade of direct or indirect effect to the ...

Immunome, Inc. (the "Company") (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class ...

The German drug company Merck KGaA will purchase the oncology biotech SpringWorks Therapeutics for $3.9 billion, in a deal that is expected to close in the second half of the year. Based in Stamford, ...

Aberrant constitutive activation of Notch homolog-1 (NOTCH1) signaling is a hallmark of T cell acute lymphoblastic leukemia (T-ALL). Gamma-secretase inhibitors (GSIs), which block NOTCH1 activation, ...

Scientists have uncovered how certain genetic mutations lead to Alzheimer’s, not by producing toxic proteins, but by halting a crucial protein-processing mechanism. This stalled process may hold the ...

From the Damian Green Lab, in collaboration with the Geoff Hill and Riddell Labs, Translational Sciences and Therapeutics Division and David Coffey, Division of Myeloma, at the University of Miami To ...